Bisoprolol and Metoprolol in the Prophylactic Treatment of Migraine with and without Aura - A Randomized Double-Blind Cross-Over Mulitcenter Study

Wörz, R; Reinhardt-Benmalek, Barbara; Grotemeyer, Karl-Heinz; Föh, M

doi:10.1177/0333102491011s1182

Cited by 17 publications

(8 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Betablockers are clearly effective in migraine prophylaxis and very well studied in a lot of placebo-controlled, randomized trials. The best evidence has been obtained for metoprolol [87][88][89][90][91] and propranolol [87,88,[92][93][94][95][96][97][98]. Also, bisoprolol [91,99], timolol [93,100], and atenolol [101] might be effective but evidence is less convincing compared with propranolol and metoprolol.…”

Section: Betablockersmentioning

confidence: 99%

EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force

Evers

Áfra²,

Frese

et al. 2009

Euro J of Neurology

694

556

View full text Add to dashboard Cite

Background: Migraine is one of the most frequent disabling neurological conditions with a major impact on the patientsÕ quality of life. Objectives: To give evidence-based or expert recommendations for the different drug treatment procedures in the particular migraine syndromes based on a literature search and the consensus of an expert panel. Methods: All available medical reference systems were screened for the range of clinical studies on migraine with and without aura and on migraine-like syndromes. The findings in these studies were evaluated according to the recommendations of the European Federation of Neurological Societies (EFNS) resulting in level A, B, or C recommendations and good practice points. Recommendations: For the acute treatment of migraine attacks, oral non-steroidal antiinflammatory drug (NSAID) and triptans are recommended. The administration should follow the concept of stratified treatment. Before intake of NSAID and triptans, oral metoclopramide or domperidone is recommended. In very severe attacks, intravenous acetylsalicylic acid or subcutaneous sumatriptan are drugs of first choice. Status migrainosus can be treated by cortoicosteroids, although this is not universally held to be helpful, or dihydroergotamine. For the prophylaxis of migraine, betablockers (propranolol and metoprolol) flunarizine, valproic acid, and topiramate are drugs of first choice. Drugs of second choice for migraine prophylaxis include amitriptyline, naproxen, petasites, and bisoprolol.

show abstract

Section: Betablockersmentioning

confidence: 99%

EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force

Evers

Áfra²,

Frese

et al. 2009

Euro J of Neurology

694

556

View full text Add to dashboard Cite

show abstract

“…Moreover, some β-adrenoceptor blockers have high affinity for certain 5-HT receptor subtypes (Cruickshank and Prichard 1994). The β 1 -adrenoceptor affinity appears to play a major role in determining prophylactic efficacy since nonselective agents such as propranolol, moderately β 1 -selective agents such as metoprolol, and highly β 1 -selective drugs such as bisoprolol (van de Ven et al 1997;Würz et al 1991) all are effective prophylactics. Thus, concomitant blockade of β 2 -adrenoceptors does not appear to be required for effective migraine prophylaxis.…”

Section: β-Adrenoceptorsmentioning

confidence: 99%

Current and prospective pharmacological targets in relation to antimigraine action

Mehrotra

Gupta

Chan

et al. 2008

Naunyn-Schmied Arch Pharmacol

View full text Add to dashboard Cite

Migraine is a recurrent incapacitating neurovascular disorder characterized by unilateral and throbbing headaches associated with photophobia, phonophobia, nausea, and vomiting. Current specific drugs used in the acute treatment of migraine interact with vascular receptors, a fact that has raised concerns about their cardiovascular safety. In the past, α-adrenoceptor agonists (ergotamine, dihydroergotamine, isometheptene) were used. The last two decades have witnessed the advent of 5-HT 1B/1D receptor agonists (sumatriptan and second-generation triptans), which have a well-established efficacy in the acute treatment of migraine. Moreover, current prophylactic treatments of migraine include 5-HT 2 receptor antagonists, Ca 2+ channel blockers, and β-adrenoceptor antagonists. Despite the progress in migraine research and in view of its complex etiology, this disease still remains underdiagnosed, and available therapies are underused. In this review, we have discussed pharmacological targets in migraine, with special emphasis on compounds acting on 5-HT (5-HT 1-7 ), adrenergic (α 1 , α 2, and β), calcitonin gene-related peptide (CGRP 1 and CGRP 2 ), adenosine (A 1 , A 2 , and A 3 ), glutamate (NMDA, AMPA, kainate, and metabotropic), dopamine, endothelin, and female hormone (estrogen and progesterone) receptors. In addition, we have considered some other targets, including gamma-aminobutyric acid, angiotensin, bradykinin, histamine, and ionotropic receptors, in relation to antimigraine therapy. Finally, the cardiovascular safety of current and prospective antimigraine therapies is touched upon.

show abstract

“…Betablockers are clearly effective in migraine prophylaxis and very well studied in a lot of placebo-controlled, randmized trials. The best evidence has been obtained for the selective betablocker metoprolol [69][70][71][72][73] and for the non-selective betablocker propranolol [69,70,[74][75][76][77][78][79][80]. Moreover, bisoprolol [73,81], timolol [75,82], and atenolol [83] might be effective, but evidence is less convincing compared with propranolol and metoprolol.…”

Section: Betablockersmentioning

confidence: 99%

EFNS guideline on the drug treatment of migraine – report of an EFNS task force

Evers¹,

Áfra²,

Frese³

et al. 2006

Euro J of Neurology

134

View full text Add to dashboard Cite

Migraine is one of the most frequent disabling neurological conditions with a major impact on the patientsÕ quality of life. To give evidence-based or expert recommendations for the different drug treatment procedures of the different migraine syndromes based on a literature search and an consensus in an expert panel. All available medical reference systems were screened for all kinds of clinical studies on migraine with and without aura and on migraine-like syndromes. The findings in these studies were evaluated according to the recommendations of the EFNS resulting in level A,B, or C recommendations and good practice points. For the acute treatment of migraine attacks, oral non-steroidal anti-inflammatory drugs (NSAIDs) and triptans are recommended. The administration should follow the concept of stratified treatment. Before intake of NSAIDs and triptans, oral metoclopramide or domperidon is recommended. In very severe attacks, intravenous acetylsalicylic acid or subcutaneous sumatriptan are drugs of first choice. A status migrainosus can probably be treated by steroids. For the prophylaxis of migraine, betablockers (propranolol and metoprolol), flunarizine, valproic acid, and topiramate are drugs of first choice. Drugs of second choice for migraine prophylaxis are amitriptyline, naproxen, petasites, and bisoprolol.

show abstract

Bisoprolol and Metoprolol in the Prophylactic Treatment of Migraine with and without Aura - A Randomized Double-Blind Cross-Over Mulitcenter Study

Cited by 17 publications

References 3 publications

EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force

EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force

Current and prospective pharmacological targets in relation to antimigraine action

EFNS guideline on the drug treatment of migraine – report of an EFNS task force

Contact Info

Product

Resources

About